News

Preliminary results for the Phase 2 LARIAT clinical trial conducted by Reata Pharmaceuticals for bardoxolone methyl in pulmonary arterial hypertension will be presented at the upcoming 2015 American College of Chest Physicians (CHEST) annual meeting in Montreal, Canada. Ronald Oudiz, MD, Professor of Medicine in David Geffen School of Medicine…

Late stage cell therapy developer Cytori Therapeutics, a company creating autologous cell therapies from adipose tissue to treat a variety of medical conditions, recently published its findings from a 12-month clinical follow-up of scleroderma patients who were enrolled in the Scleradec-I clinical trial on hand dysfunction associated with the disease. The Scleradec-I study, an…

A study was recently conducted to determine levels of vascular endothelial growth factor in the tears of patients with scleroderma. Vascular endothelial growth factor or VEGF has been found to play a major role in the development of new blood vessels in a number of diseases, including macular degeneration of the eye, diabetic…

In a recent study published in Fibrogenesis & Tissue Repair entitled “Enhanced chemokine-receptor expression, function, and signaling in healthy African American and scleroderma-patient monocytes are regulated by caveolin-1,” scientists from Medical University of South Carolina reported new insights into the mechanism of…

Corbus Pharmaceuticals Holdings, Inc. a clinical stage drug development company targeting chronic, rare, and serious inflammatory and fibrotic diseases with clear unmet needs, recently announced the initiation of patient enrollment for its Phase 2 trial of Resunab™ for the treatment of diffuse cutaneous systemic sclerosis. Systemic Sclerosis (Scleroderma) is a…

This week, Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), a clinical stage drug development company targeting rare, chronic, and serious inflammatory and fibrotic diseases, announced that Resunab™, has been granted Fast Track status for the clinical investigation of  by the U.S. Food and Drug Administration (FDA) for the treatment of systemic sclerosis…

A new study recently published in the journal Arthritis Research & Therapy provides encouraging data on a pilot study evaluating nilotinib (Tasigna™) as a therapy for diffuse systemic sclerosis. The study is entitled “Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis:…

Systemic sclerosis (also referred to as “Scleroderma” and abbreviated as SSc) is an abnormal immune response of the body that leads to an overproduction of collagen. This overproduction of collagen and inflammation associated with SSc can negatively affect organs like the skin, lungs, digestive tract and kidneys. However, the most visible…

Tiny pieces of damaged endothelial cells, aptly called “microparticles” due to their size, can be generated in patients with systemic sclerosis (SSc). These cell particulates are created from a variety of processes, but are often the result of inflammation or shear stress from blood flow in narrowed arteries. Since pulmonary arterial…

According to a news release, it was recently revealed at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology, on June 2015 that the drug iloprost can mitigate Raynaud’s syndrome and prevent the development of digital ulcers. Raynaud’s syndrome is a disorder characterized by excessively reduced blood flow…